Change to Executive Board of Carl Zeiss Meditec AG
Jena/Germany | Carl Zeiss Meditec AG
- President and CEO Dr. Ludwin Monz will be stepping down from the Executive Board of Carl Zeiss Meditec AG at his own request and by amicable agreement on 31 December 2021.
- He will be succeeded by Dr. Markus Weber effective 1 January 2022. Dr. Weber is currently a member of the Executive Board of Carl Zeiss AG and is responsible for the ZEISS Semiconductor Manufacturing Technology segment.
President and CEO of Carl Zeiss Meditec AG, Dr. Ludwin Monz, has announced to the Supervisory Board that he will not be accepting another term in office. The Supervisory Board notes his decision with regret. Today, Dr. Monz and the Supervisory Board agreed to end his term on 31 December 2021.
The Supervisory Board has appointed Dr. Markus Weber the new President and CEO of Carl Zeiss Meditec AG effective 1 January 2022. As a member of the Executive Board of Carl Zeiss AG, he is currently responsible for the Semiconductor Manufacturing Technology segment and will relinquish his current duties on 31 December 2021.
"The Supervisory Board of Carl Zeiss Meditec AG would like to thank Dr. Monz for his outstanding commitment and the incredible success he has had during his tenure as President and CEO of Carl Zeiss Meditec AG. He has helped the company to evolve in a distinct and lasting manner and shaped it into one of eastern Germany's major listed companies. He has transformed Carl Zeiss Meditec AG into a technology leader in ophthalmology and microsurgery," said Dr. Karl Lamprecht, Chairman of the Supervisory Board of Carl Zeiss Meditec AG and President and CEO of Carl Zeiss AG. "We were saddened to hear of Dr. Monz' decision not to stand for another term, but we certainly wish him all the best going forward."
Dr. Monz also thanked the Supervisory Board for its trust and collaboration: "We can look back on many incredibly exciting and successful years here at Carl Zeiss Meditec AG. I would like to thank the Supervisory Board for its exceptional support over the years. I'd also like to thank all of our customers, partners and, of course, all of our esteemed employees for their longstanding and exceptional collaboration. Furthermore, I wish my successor, Dr. Markus Weber, all the best going forward."
Dr. Karl Lamprecht is delighted to have found such a highly skilled successor in Dr. Weber from the ZEISS Group's own ranks: "In Dr. Weber's 20 years at ZEISS, he has held a variety of management positions, gained a tremendous amount of experience and made a substantial impact on the ZEISS Group, be it in his role in Microsurgery at Carl Zeiss Meditec AG or as Head of the Research Microscopy Solutions business unit. In this role in particular, he was able to gain a deep customer understanding and build up a customer network in the life sciences," said Dr. Lamprecht. "Dr. Weber has an excellent grasp of technology and sound skills in innovation management."
Dr. Weber spoke about his appointment as President and CEO of Carl Zeiss Meditec AG: "I am very much looking forward to my new role at Carl Zeiss Meditec AG. Supported by megatrends such as the digital transformation, health and demographic developments, the importance of innovative medical technology will only increase further. Carl Zeiss Meditec has positioned itself very well here. We will leverage this solid foundation and continue maximizing its potential."
Effective 1 January 2022, alongside Dr. Weber as President and CEO, the three-member Executive Board of Carl Zeiss Meditec AG will continue to comprise Mr. Justus Wehmer as Chief Financial Officer and Mr. Jan Willem de Cler, who is responsible forHuman Resources, Global Service & Customer Care, and Operations.
Dr. Ludwin Monz has been at the helm of Carl Zeiss Meditec AG since March 2010, and has been a member of the Executive Board of Carl Zeiss Meditec AG since 2007. Moreover, on 1 January 2014 he was appointed a member of the Executive Board of Carl Zeiss AG. In this role, Dr. Monz is responsible for Corporate Quality Management. He looks after the sales regions of Japan, Spain, France and Turkey. After completing degrees and a doctorate in physics at the University of Mainz, he worked at the National Institute of Standards and Technology in Gaithersburg, USA, and at the GSI Gesellschaft für Schwerionenforschung (Center for Heavy Ion Research) in Darmstadt, as a scientist. He also holds an MBA from Henley Management College in Great Britain. He joined ZEISS in 1994 as a scientist, and two years later became Head of Geodetic Systems Development, before assuming overall responsibility for the business area. In 2000 he moved to ZEISS Medical Technology.
Dr. Markus Weber earned his undergraduate degrees and his doctorate at the universities of Karlsruhe and Ulm. He joined ZEISS Semiconductor Manufacturing Technology in 2002 as a research associate. After holding a series of management positions in a variety of departments, in 2009 Dr. Weber became Head of Advanced Development in the Microsurgery business area of the Medical Technology business group. In 2010 Dr. Weber then became Head of Corporate Research and Technology for the ZEISS Group. 2015 saw him accept a role as Head of the Research Microscopy Solutions SBU, before also becoming Head of the Industrial Quality Research segment in 2018. A year later, in 2019, Dr. Weber was appointed a member of the Executive Board of Carl Zeiss AG. He assumed responsibility for the ZEISS Semiconductor Manufacturing Technology segment, for the Shared Production Unit and for the Korea sales region.
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For more information visit our website at www.zeiss.com/med